Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Thalidomide (THAL) and Lenalidomide (LEN)-Associated Venous Thromboembolism (VTE): Optimal Prophylaxis Strategies Remain Elusive

June M. McKoy, MD, JD, MPH, MBA, Dustin B Liebling, BA, Alfred W. Rademaker, PhD, Bing Bing Weitner, MS, Beatrice J. Edwards, MD, MPH, Steven M. Belknap, MD, Andrew Thurston, MD, Monica Boen, MD, Katrina-Marie E Tulas, BA, Judith M McKoy-Bent, BA, BSN, Jowella Pineda, MD, Dennis P. West, PhD

Blood (2012) 120 (21): 4692.

https://doi.org/10.1182/blood.V120.21.4692.4692

Published: 2012

Journal Articles

Anaphylaxis Associated with Administration of Repeated Courses of Rasburicase: A Research On Adverse Drug Events and Reports (RADAR) Project

Katherine C Allen, PharmD, Amanda H Champlain, MD, Jonathan Cotliar, MD, Steven M. Belknap, MD, Dennis P. West, PhD, Jayesh Mehta, MD, Steven Trifilio

Blood (2012) 120 (21): 1351.

https://doi.org/10.1182/blood.V120.21.1351.1351

Published: 2012

Journal Articles

Erythropoietin Stimulating Agents (ESAs): Reassessment of Use in Cancer and Chronic Kidney Disease (CKD) Settings in the United States, Canada, and Europe.

Charles L Bennett, MD, PhD, Athena T Samaras, BA, June M McKoy, MD, JD, MPH, Beatrice J Edwards, MD, FACP, Mi Zheng, Matthew J Fisher, BA, Simone N Boyle, BA, Steven M Trifilio, RPh, Monica Boen, BA, Dianne Deleon, BA, Dennis P West, PhD

Blood (2009) 114 (22): 4538.

https://doi.org/10.1182/blood.V114.22.4538.4538

Published: 2009

Journal Articles

From Bench to Bedside: Hematopoietic Growth Factors (HGFs)- a Cause of Serious and Unanticipated Class Toxicities.

Charles L. Bennett, MD, PhD, Ari Polish, MD, Athena T Samaras, BA, Mi Zheng, Dennis P West, PhD, Steven M Trifilio, RPh, Beatrice J Edwards, MD, FACP, Simone N Boyle, BA, Matthew J Fisher, June M McKoy, MD, JD, MPH

Blood (2009) 114 (22): 4555.

https://doi.org/10.1182/blood.V114.22.4555.4555

Published: 2009

Journal Articles

Evaluation of Conflicts of Interest in Basic Science Studies Evaluating Erythropoietin and Erythropoietin Effects of Solid Cancer Cell Lines

Sara E Barnato, MD, Simone N Boyle, BA, Adam Kuykendal, MD, Stephen Y Lai, MD, PhD, Robin L Wagner, Carolyn E Goldstein, Athena T Samaras, BA, Dennis P West, PhD, Jacob Tallman, Michael Henke, MD, A. Oliver Sartor, MD, Charles L. Bennett, MD, PhD, MPP

Blood (2008) 112 (11): 672.

https://doi.org/10.1182/blood.V112.11.672.672

Published: 2008

Journal Articles

Novel Dissemination Efforts for Hematology-Related Serious Adverse Drug Reactions (sADRs): Findings from the Research on Adverse Drug Events and Reports Project (RADAR)

Cara C Tigue, BA, Dennis P West, PhD, Dennis W Raisch, PhD, RPh, Beatrice J Edwards, MD, FACP, Simone N Boyle, BA, Athena T Samaras, BA, Paul Bennett, Charles L. Bennett, MD, PhD, MPP

Blood (2008) 112 (11): 4662.

https://doi.org/10.1182/blood.V112.11.4662.4662

Published: 2008

Journal Articles

Erythropoiesis Stimulating Agent (ESA) Use for Anemic Cancer and Chronic Kidney Disease (CKD) Patients in 2008: Advocacy for Conservative Use

Charles L. Bennett, MD, PhD, MPP, Benjamin Kim, MD, Athena T Samaras, BA, Allen R Nissenson, MD, FACP, A. Oliver Sartor, MD, D. Mark Courtney, MD, Robert I. Liem, MD, Dennis P West, PhD, Simone N Boyle, BA, Robin L Wagner, Carolyn E Goldstein, Steven M Trifilio, RPh, David M Spiegel, MD, FACP, Stephen Y Lai, MD, PhD

Blood (2008) 112 (11): 4680.

https://doi.org/10.1182/blood.V112.11.4680.4680

Published: 2008

Journal Articles

Rapid Identification of Hematology-Associated Serious Adverse Drug Reactions (sADRS) with Small Datasets: Findings from the Research on Adverse Drug Events and Reports (RADAR) Project.

Nina Undevia, MD MPH, Cara C. Tigue, BA, Dennis P. West, PhD, June M. McKoy, MD MPH JD, Beatrice J. Edwards, MD, David A. Dorr, MD MS, Dennis W. Raisch, RPh PhD, Charles L. Bennett, MD, PhD, MPP

Blood (2007) 110 (11): 3339.

https://doi.org/10.1182/blood.V110.11.3339.3339

Published: 2007

Journal Articles

Evaluating Mortality with Erythropoietic Stimulating Agents (ESAs) in the Nephrology Setting: The Distinction between Evaluating Trials That Measure Survival as a Primary or Secondary Efficacy Endpoint Versus a Safety Endpoint.

Sara E. Barnato, MD, Charles L. Bennett, MD PhD MPP, Kathleen Elverman, Dennis P. West, PhD, Mark Courtney, MD

Blood (2007) 110 (11): 962.

https://doi.org/10.1182/blood.V110.11.962.962

Published: 2007

NARROW

Thalidomide (THAL) and Lenalidomide (LEN)-Associated Venous Thromboembolism (VTE): Optimal Prophylaxis Strategies Remain Elusive

Anaphylaxis Associated with Administration of Repeated Courses of Rasburicase: A Research On Adverse Drug Events and Reports (RADAR) Project

Erythropoietin Stimulating Agents (ESAs): Reassessment of Use in Cancer and Chronic Kidney Disease (CKD) Settings in the United States, Canada, and Europe.

From Bench to Bedside: Hematopoietic Growth Factors (HGFs)- a Cause of Serious and Unanticipated Class Toxicities.

Evaluation of Conflicts of Interest in Basic Science Studies Evaluating Erythropoietin and Erythropoietin Effects of Solid Cancer Cell Lines

Novel Dissemination Efforts for Hematology-Related Serious Adverse Drug Reactions (sADRs): Findings from the Research on Adverse Drug Events and Reports Project (RADAR)

Erythropoiesis Stimulating Agent (ESA) Use for Anemic Cancer and Chronic Kidney Disease (CKD) Patients in 2008: Advocacy for Conservative Use

Rapid Identification of Hematology-Associated Serious Adverse Drug Reactions (sADRS) with Small Datasets: Findings from the Research on Adverse Drug Events and Reports (RADAR) Project.

Evaluating Mortality with Erythropoietic Stimulating Agents (ESAs) in the Nephrology Setting: The Distinction between Evaluating Trials That Measure Survival as a Primary or Secondary Efficacy Endpoint Versus a Safety Endpoint.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only